treatment of palmar psoriasis by methotrexate solutio

Phase 3

Completed

• Conditions: Health Condition 1: L408- Other psoriasisHealth Condition 2: null- palmoplantar psoriasis

• Registration Number: CTRI/2017/09/009803
• Lead Sponsor: Hassan institute of medical sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

1)Palmoplantar psoriasis patients of more than 18 years of age, with lesions preferably on palms but not involving more than 10% surface area of soles and not involving more than 5% of other body surface area.

2)Patients who are not on systemic anti-psoriatic medication for atleast one month or topical anti-psoriatic medication for atleast 15 days prior to the study.

3)Patients who are willing to participate in the study.

Exclusion Criteria

1)Palmoplantar pustular psoriasis patients.

2)Pregnant and lactating women.

3)Female patients of child bearing potential who cannot be convinced of the need of contraception during and 4 months subsequent to the conclusion of study.

4)Patients with cardiac pace makers or orthopedic implants in the extremities.

5)Patients having haematological abnormality, hepatic and renal dysfunction.

6)Patients having any infection of palms and soles.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
improvement in modified Palmo Plantar Pustular Psoriasis Area and Severity Index (m-PPPASI)Timepoint: after 6 weeks of treatment

Secondary Outcome Measures

Name	Time	Method
adverse effects of treatment and recurrenceTimepoint: follow up for 6 weeks after treatment